- Home
- TSI vs SLGL Comparison
TSI vs SLGL Comparison
Compare TSI & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSI | SLGL |
|---|---|---|
| Founded | 1987 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.7M | 247.1M |
| IPO Year | 1995 | 2016 |
Fundamental Metrics
Financial Performance| Metric | TSI | SLGL |
|---|---|---|
| Price | $4.51 | $83.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 255.8K | 19.6K |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.43 | $0.40 |
| 52 Week High | $5.06 | $97.97 |
Technical Indicators
Market Signals| Indicator | TSI | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 53.34 |
| Support Level | N/A | $66.47 |
| Resistance Level | $4.95 | $95.83 |
| Average True Range (ATR) | 0.07 | 10.01 |
| MACD | -0.01 | -0.47 |
| Stochastic Oscillator | 27.11 | 66.70 |
Price Performance
Historical ComparisonAbout TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.